Reading SMTI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SMTI free→Reading SMTI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SMTI free→QuarterlyIQ Insights · SMTI
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Termination of a Material Definitive Agreement. As previously disclosed, on March 20, 2023, Sanara MedTech Inc. (the “Company”) entered into a Transaction Advisory Services Agreement (the “Services Agreement”) with The Catalyst Group, Inc., a Texas corporation (“Catalyst”), effective as of March 1, 2023. Pursuant to the Services Agreement, Catalyst agreed to perform certain transaction advisory, business and organizational strategy, finance, marketing, operational and strategic planning, rela…
Results of Operations and Financial Condition. On May 11, 2026, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 18 of the Secur…
Results of Operations and Financial Condition. On March 24, 2026, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 1…
Results of Operations and Financial Condition. On January 23, 2026, Sanara MedTech Inc. (the “Company”) issued a press release announcing certain preliminary financial results for the fourth quarter and full year 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes o…
Results of Operations and Financial Condition. On November 11, 2025, Sanara MedTech Inc. (the “Company”) issued a press release announcing that it has initiated a strategic realignment of its business, discontinuing operations of its Tissue Health Plus. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall n…
Results of Operations and Financial Condition. On November 12, 2025, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 18 of…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of New Chief Executive Officer and Director On August 29, 2025, the Board of Directors (the “Board”) of Sanara MedTech Inc. (the “Company”) (i) appointed Seth D. Yon as the President and Chief Executive Officer of the Company, including the role of principal executive officer, (ii) increased the size of the Board from eight (8) director…
Results of Operations and Financial Condition. On August 13, 2025, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 18 of the Sec…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 19, 2025, Michael D. McNeil notified Sanara MedTech Inc. (the “Company”) that he is retiring from his position as Chief Accounting Officer and Chief Administrative Officer of the Company, effective August 19, 2025 (the “Effective Date”). The Company is currently in discussions with Mr. McNeil regarding a consulting arrangement, pursuant to w…
Results of Operations and Financial Condition. On May 14, 2025, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 18 of the Secur…
Entry into a Material Definitive Agreement. CarePICS Acquisition On April 1, 2025 (the “Closing Date”), Sanara MedTech Inc., a Texas corporation (the “Company”), entered into a Unit Purchase Agreement (the “Purchase Agreement”), by and among the Company, Tissue Health Plus, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (the “Purchaser”), CarePICS, LLC, a Delaware limited liability company (“CarePICS”), the holders of CarePICS’s outstanding units (each, a…
Other Events. On March 31, 2025, the Company, pursuant to its option under its previously disclosed Term Loan Agreement with CRG Servicing LLC, dated as of April 17, 2024 (as amended on March 19, 2025, the “Loan Agreement”) borrowed an additional $12.25 million under the Loan Agreement (the “Third Borrowing”). As previously disclosed, the Loan Agreement provides for up to a $55.0 million term loan facility, $15.0 million of which was borrowed on April 17, 2024 (the “First Borrowing”) and $15.…
Completion of Acquisition or Disposition of Assets. The information set forth in
Results of Operations and Financial Condition. On March 25, 2025, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2024. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 1…
Entry into a Material Definitive Agreement. The information set forth in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of New Chief Financial Officer On January 15, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of Sanara MedTech Inc. (the “Company”) appointed Elizabeth B. Taylor to serve as the Chief Financial Officer of the Company, including the role of principal financial officer, effective as of the Effective Date. Ms. Taylor, ag…
Other Events. Licensing and Distribution Agreement On January 16, 2025 (the “Execution Date”), the Company entered into a Licensing and Distribution Agreement (the “License Agreement”), by and between the Company and Biomimetic Innovation Limited, a privately-held medical device company headquartered in Shannon, Co. Clare Ireland (“BMI”), pursuant to which the Company acquired the exclusive U.S. marketing, sales and distribution rights to OsStic ® Synthetic Injectable Structural Bio-Adhesive…
Results of Operations and Financial Condition. On January 21, 2025, Sanara MedTech Inc. (the “Company”) issued a press release announcing certain preliminary financial results for the fourth quarter and full year 2024. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes o…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.